

Novavax to Participate in Upcoming September Conferences

September 7, 2022

GAITHERSBURG, Md., Sept. 7, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

H.C. Wainwright 24th Annual Global Investment Conference:

Fireside Chat

Date: Monday, September 12, 2022
Time: 4:00 – 4:30 p.m. Eastern Daylight Time (EDT)
Location: Lotte New York Palace Hotel
Moderator: Vernon Bernardino
Novavax participants: Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer

Baird 2022 Global Healthcare Conference:

Fireside Chat

Date: Tuesday, September 13, 2022
Time: 8:30 – 9:00 a.m. Eastern Daylight Time (EDT)
Location: Intercontinental New York Barclay Hotel
Moderator: Joel L. Beatty, M.D., CFA
Novavax participants: Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer

Conference

Event: Investor Meetings
Date: Tuesday, September 13, 2022

Recordings

All replays of the recorded fireside sessions will be available through the Events & presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine has received authorization from multiple regulatory authorities globally, including the U.S., European Commission and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on [LinkedIn](#).

*NanoFlu? identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.

Contacts:Investors

Erika Schultz | 240-268-2022

ir@novavax.com

Media

Ali Chartan or Giovanna Chandler | 240-709-5563

media@novavax.com

SOURCE Novavax, Inc.

Image not found or type unknown